Myriad Genetics Inc (NASDAQ: MYGN) has reported a loss for its third fiscal quarter (ending September 30) of $-0.24 versus a loss $-0.75 for the same period a year ago — a decline of -68%. E.P.S. were $-1.30 for the latest four quarters through September 30 versus $-3.36 for the same period a year ago — a decline of -61%.
Recent Price Action
Myriad Genetics Inc (NASDAQ: MYGN) stock rose modestly by 0.6% on 11/7/24. The stock closed at $17.67. Moreover, above average trading volume at 123% of normal accompanied the advance. Relative to the market the stock has been strong over the last nine months but has declined -22.4% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to exceed the cost of capital, MYGN is expected to continue to be a modest Value Builder.
Myriad Genetics has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Myriad Genetics has a poor Appreciation Score of 17 but a good Power Rating of 78, resulting in the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment